What is Leerink Partnrs’ Estimate for Pharvaris Q3 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of Pharvaris in a research note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($0.89). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.64) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($3.27) EPS and FY2027 earnings at ($2.14) EPS.

A number of other brokerages also recently weighed in on PHVS. JMP Securities reduced their target price on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Guggenheim began coverage on Pharvaris in a report on Wednesday, June 11th. They set a “buy” rating and a $32.00 price objective on the stock. Wedbush reissued an “outperform” rating and set a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th. Finally, Cantor Fitzgerald cut their price objective on Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $35.60.

Pharvaris Stock Performance

Shares of PHVS stock opened at $22.30 on Monday. The stock’s fifty day moving average price is $19.71 and its two-hundred day moving average price is $17.23. The company has a market cap of $1.17 billion, a PE ratio of -6.64 and a beta of -2.81. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $26.33.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07).

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently modified their holdings of PHVS. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after acquiring an additional 2,847 shares in the last quarter. Geode Capital Management LLC raised its position in Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after purchasing an additional 1,356 shares during the last quarter. Legal & General Group Plc raised its position in Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock worth $189,000 after purchasing an additional 994 shares during the last quarter. Rock Springs Capital Management LP raised its position in Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock worth $14,859,000 after purchasing an additional 18,200 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Pharvaris by 36.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.